Drug intelligence / Profile preview

NP-02

Development stage: Preclinical
Lead developer: CNBX Pharmaceuticals
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

NP-02 is a psychedelic-inspired, cannabinoid-based drug candidate being developed by Cannabics Pharmaceuticals (also known as CNBX Pharmaceuticals) for the treatment of various neuropsychiatric indications. The drug is part of the company's specialized program focused on mental health conditions with significant unmet needs, led by neuropsychiatrist Dr. Ilya Reznik. NP-02 is identified through the company's proprietary high-throughput screening (HTS) technology and advanced bioinformatics platform, which aims to optimize cannabinoid-molecule formulations for therapeutic efficacy. As of the latest reports, the candidate is in the discovery phase of development, and specific details regarding its active ingredients and molecular targets remain proprietary.

Beyond the preview

Go deeper on NP-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-02.

Explore the full profile